Bayer and Evotec collaborate to advance precision cardiology

EQS-News: Evotec SE / Key word(s): Miscellaneous
Bayer and Evotec collaborate to advance precision cardiology

30.04.2024 / 08:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

  * BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR
    DISEASES

  * STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE
    MODELLING FOR IDENTIFICATION OF NOVEL TARGETS

  * JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION
    CARDIOLOGY

Berlin and Hamburg, Germany, 30 April 2024:
Bayer and the German-based life science company, Evotec, announced today
that they have updated the focus of their strategic collaboration to
developing innovative precision treatments for cardiovascular diseases
(CVDs).

The collaboration aims to identify and validate novel targets, with the goal
of building a portfolio of precision cardiology therapeutics by leveraging
Evotec's disease modelling capabilities using human induced pluripotent stem
cells (iPSCs). iPSCs provide unique opportunities to identify new disease
mechanisms and pathways for novel treatments.

Under the terms of the agreement, both companies will contribute drug
targets and a comprehensive set of high-quality technology platforms for the
development of innovative treatment options.

"This development takes our long-standing collaboration with Evotec to a new
level, and has the added benefit of lessons learned from working together
the past 12 years," said Juergen Eckhardt, M.D., Head of Business
Development & Licensing at Bayer's Pharmaceuticals Division. "We remain
committed to develop innovative therapies for patients in need and to tackle
the high burden of cardiovascular disease."

"Cardiovascular diseases are the leading cause of death globally," said Dr
Christian Rommel, Head of Research and Development at Bayer's
Pharmaceuticals Division. "The refocused collaboration will leverage
Evotec's industrialised iPSC-based disease modelling platform and Bayer's
leadership in cardiology to advance a portfolio of innovative therapies for
cardiovascular diseases with high unmet medical need. This complements our
focus on disease areas where we can truly improve the standard of care by
delivering superior therapeutic solutions to patients in need."

"In order to move the treatment paradigm beyond disease management, it is
important to advance our understanding of the disease-relevant molecular
mechanisms underlying cardiovascular diseases," said Dr Cord Dohrmann, Chief
Scientific Officer of Evotec. "Our approach is based on highly validated
disease models to identify novel targets and profile drug candidates more
comprehensively for their efficacy and safety. Intervening with these
disease-associated mechanisms more comprehensively will enable the
development of more effective, disease modifying therapies with higher
relevance for CVD to respond to the substantial unmet need associated with
cardiovascular diseases."

Bayer and Evotec will share responsibilities during the pre-clinical
development of potential clinical candidates. Bayer will be responsible for
any subsequent clinical development and commercialisation.

No financial terms of the collaboration were disclosed.


ABOUT BAYER
Bayer is a global enterprise with core competencies in the life science
fields of health care and nutrition. In line with its mission, "Health for
all, Hunger for none," the company's products and services are designed to
help people and the planet thrive by supporting efforts to master the major
challenges presented by a growing and aging global population. Bayer is
committed to driving sustainable development and generating a positive
impact with its businesses. At the same time, the Group aims to increase its
earning power and create value through innovation and growth. The Bayer
brand stands for trust, reliability and quality throughout the world. In
fiscal 2023, the Group employed around 100,000 people and had sales of 47.6
billion euros. R&D expenses before special items amounted to 5.8 billion
euros. For more information, go to www.bayer.com.

Bayer Media Contact:
Lisa Hennig, phone +49 172 8693420
Email: lisa.hennig@bayer.com

ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers
on its mission to discover and develop highly effective therapeutics and
make them available to the patients. The Company's multimodality platform
comprises a unique combination of innovative technologies, data and science
for the discovery, development, and production of first-in-class and
best-in-class pharmaceutical products. Evotec provides high value pipeline
co-creating partnerships and solutions to all Top 20 Pharma and over 800
biotechnology companies, academic institutions, as well as other healthcare
stakeholders. Evotec has strategic activities in a broad range of currently
underserved therapeutic areas, including e.g. neurology, oncology, as well
as metabolic and infectious diseases. Within these areas of expertise,
Evotec aims to create the world-leading co-owned pipeline for innovative
therapeutics and has to-date established a portfolio of more than 200
proprietary and co-owned R&D projects from early discovery to clinical
development. Evotec operates globally with more than 5,000 highly qualified
people. The Company's 17 sites offer highly synergistic technologies and
services and operate as complementary clusters of excellence. For additional
information please go to www.evotec.com and follow us on X/Twitter @Evotec
and LinkedIn.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future
events, including the proposed offering and listing of Evotec's securities.
Words such as "anticipate," "believe," "could," "estimate," "expect,"
"intend," "may," "might," "plan," "potential," "should," "target," "would"
and variations of such words and similar expressions are intended to
identify forward-looking statements. Such statements include comments
regarding Evotec's expectations for revenues, Group EBITDA and unpartnered
R&D expenses. These forward-looking statements are based on the information
available to, and the expectations and assumptions deemed reasonable by
Evotec at the time these statements were made. No assurance can be given
that such expectations will prove to have been correct. These statements
involve known and unknown risks and are based upon a number of assumptions
and estimates, which are inherently subject to significant uncertainties and
contingencies, many of which are beyond the control of Evotec. Evotec
expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Evotec's expectations with respect thereto or any
change in events, conditions or circumstances on which any statement is
based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications,
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder, Director of Global Corporate Communications,
Hinnerk.Rohwedder@evotec.com

IR Contact Evotec SE:
Volker Braun, EVP Head of Global Investor Relations & ESG,
Volker.Braun@evotec.com


---------------------------------------------------------------------------

30.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Evotec SE
                   Manfred Eigen Campus / Essener Bogen 7
                   22419 Hamburg
                   Germany
   Phone:          +49 (0)40 560 81-0
   Fax:            +49 (0)40 560 81-222
   E-mail:         info@evotec.com
   Internet:       www.evotec.com
   ISIN:           DE0005664809
   WKN:            566480
   Indices:        MDAX, TecDAX
   Listed:         Regulated Market in Berlin, Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Dusseldorf, Hamburg,
                   Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
   EQS News ID:    1892043

End of News EQS News Service
---------------------------------------------------------------------------

1892043 30.04.2024 CET/CEST